CA242在胃肠道癌中的敏感性和特异性。与癌胚抗原（CEA）、CA50和CA19-9的比较。
Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
作者信息
Nilsson O, Johansson C, Glimelius B, Persson B, Nørgaard-Pedersen B, Andrén-Sandberg A, Lindholm L
机构信息
Pharmacia CanAg, Göteborg, Sweden.
出版信息
Br J Cancer. 1992 Feb;65(2):215-21. doi: 10.1038/bjc.1992.44.
Abstract
A serological assay for the quantitative determination of the novel tumour-associated epitope CA242 was developed and used for determination of sensitivity and specificity of CA242 in gastrointestinal cancer. The CA242 assay showed a better tumour specificity than CA50 (and CA 19-9). This was most noticeable in benign hepatobiliary disease. The sensitivity at 90% specificity cut-off level was approximately three times higher for CA242 compared to CA50 in colo-rectal cancer Dukes A, B and C, while in pancreatic cancer the sensitivity of CA242 and CA50 was similar. CA242 was expressed independently of CEA, and the combination of CEA and CA242 gave in colo-rectal cancer considerably higher sensitivity than the use of only one of the markers. This was most pronounced in Dukes A and Dukes B patients. CA242 is a novel tumour marker of potential clinical use, particularly in colo-rectal cancer.
摘要
开发了一种用于定量测定新型肿瘤相关表位CA242的血清学检测方法，并用于测定CA242在胃肠道癌中的敏感性和特异性。CA242检测显示出比CA50（和CA19-9）更好的肿瘤特异性。这在良性肝胆疾病中最为明显。在结直肠癌Dukes A、B和C期，与CA50相比，CA242在90%特异性临界值水平时的敏感性约高3倍，而在胰腺癌中，CA242和CA50的敏感性相似。CA242的表达独立于CEA，在结直肠癌中，CEA和CA242联合使用的敏感性比仅使用其中一种标志物要高得多。这在Dukes A期和Dukes B期患者中最为明显。CA242是一种具有潜在临床应用价值的新型肿瘤标志物，尤其在结直肠癌中。
相似文献
1
Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.CA242在胃肠道癌中的敏感性和特异性。与癌胚抗原（CEA）、CA50和CA19-9的比较。
Br J Cancer. 1992 Feb;65(2):215-21. doi: 10.1038/bjc.1992.44.
2
The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.血清癌胚抗原（CEA）、糖类抗原19-9（CA19-9）和糖类抗原242（CA242）在胰腺癌诊断及预后中的临床价值
Eur J Surg Oncol. 2005 Mar;31(2):164-9. doi: 10.1016/j.ejso.2004.09.007.
3
Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.血清CA19-9、CEA、CA125和CA242在同步放化疗治疗的胰腺癌患者诊断及预后中的应用价值
Asian Pac J Cancer Prev. 2015;16(15):6569-73. doi: 10.7314/apjcp.2015.16.15.6569.
4
Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.血清肿瘤标志物、粪便k-ras和p53基因突变对胰腺癌的诊断价值评估。
Chin J Dig Dis. 2006;7(3):170-4. doi: 10.1111/j.1443-9573.2006.00263.x.
5
[The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].[肿瘤标志物CA50和CA242在消化道肿瘤中的临床价值]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1998 Aug;20(4):285-8.
6
Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer.血清CA199、CA242及CA50检测在胰腺癌诊断中的应用价值
J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):383-388.
7
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.CA 242，一种新型胰腺癌肿瘤标志物：与CA 19-9、CA 50和癌胚抗原的比较。
Br J Cancer. 1994 Sep;70(3):487-92. doi: 10.1038/bjc.1994.332.
8
[Detection and clinical study of serum tumor markers in patients with colorectal cancer].[结直肠癌患者血清肿瘤标志物的检测及临床研究]
Zhonghua Zhong Liu Za Zhi. 2005 May;27(5):286-8.
9
Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.CA242与CA19-9用于胰腺癌诊断的比较研究
Br J Cancer. 1994 Sep;70(3):481-6. doi: 10.1038/bjc.1994.331.
10
Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.术前血清癌胚抗原（CEA）、糖类抗原19-9（CA19-9）和糖类抗原242（CA242）联合检测可改善接受手术治疗的结直肠癌患者的预后预测。
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14853-63. eCollection 2015.
引用本文的文献
1
Tumor biomarkers for diagnosis, prognosis and targeted therapy.肿瘤标志物用于诊断、预后和靶向治疗。
Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2.
2
Vascular invasion and lymph node metastasis mediate the effect of CA242 on prognosis in hilar cholangiocarcinoma patients after radical resection.血管侵犯和淋巴结转移介导了CA242对肝门部胆管癌患者根治性切除术后预后的影响。
Front Oncol. 2022 Dec 12;12:1071439. doi: 10.3389/fonc.2022.1071439. eCollection 2022.
3
Pseudomyxoma peritonei originating from intestinal duplication: A case report and review of the literature.起源于肠重复畸形的腹膜假黏液瘤：一例报告并文献复习
World J Clin Cases. 2021 Sep 6;9(25):7459-7467. doi: 10.12998/wjcc.v9.i25.7459.
4
Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning.基于机器学习的治疗前血清肿瘤标志物的非转移性三阴性乳腺癌预后模型
J Oncol. 2021 May 15;2021:6641421. doi: 10.1155/2021/6641421. eCollection 2021.
5
Correlation study between serum neuro-specific enolase and gastric and colorectal cancers.血清神经特异性烯醇化酶与胃癌和结直肠癌的相关性研究
Medicine (Baltimore). 2020 Apr;99(16):e19796. doi: 10.1097/MD.0000000000019796.
6
The difference in prognosis of stage II and III colorectal cancer based on preoperative serum tumor markers.基于术前血清肿瘤标志物的II期和III期结直肠癌的预后差异。
J Cancer. 2019 Jun 9;10(16):3757-3766. doi: 10.7150/jca.31660. eCollection 2019.
7
Nomograms for predicting the prognostic value of serological tumor biomarkers in colorectal cancer patients after radical resection.用于预测结直肠癌根治术后患者血清肿瘤标志物预后价值的列线图。
Sci Rep. 2017 Apr 18;7:46345. doi: 10.1038/srep46345.
8
Differential Diagnosis of Immunoglobulin G4-associated Cholangitis From Cholangiocarcinoma.免疫球蛋白G4相关性胆管炎与胆管癌的鉴别诊断
J Clin Gastroenterol. 2016 Jul;50(6):501-5. doi: 10.1097/MCG.0000000000000509.
9
Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer.血清糖类抗原242表达在胰腺癌诊断中发挥关键作用。
Tumour Biol. 2014 Jun;35(6):5281-6. doi: 10.1007/s13277-014-1687-5. Epub 2014 Feb 9.
10
Serum tumor markers in pancreatic cancer-recent discoveries.血清肿瘤标志物在胰腺癌中的最新发现。
Cancers (Basel). 2010 Jun 2;2(2):1107-24. doi: 10.3390/cancers2021107.
本文引用的文献
1
The spread of rectal cancer and its effect on prognosis.直肠癌的扩散及其对预后的影响。
Br J Cancer. 1958 Sep;12(3):309-20. doi: 10.1038/bjc.1958.37.
2
Reactivity of a monoclonal antibody with human ovarian carcinoma.一种单克隆抗体与人卵巢癌的反应性。
J Clin Invest. 1981 Nov;68(5):1331-7. doi: 10.1172/jci110380.
3
Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides.作为单唾液酸神经节苷脂分离出的抗胃肠道肿瘤相关抗原的单克隆抗体。
Int Arch Allergy Appl Immunol. 1983;71(2):178-81. doi: 10.1159/000233384.
4
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.针对单克隆抗体定义的肿瘤标志物CA 19-9的放射免疫分析。
Clin Chem. 1983 Mar;29(3):549-52.
5
Europium as a label in time-resolved immunofluorometric assays.铕作为时间分辨免疫荧光分析中的标记物。
Anal Biochem. 1984 Mar;137(2):335-43. doi: 10.1016/0003-2697(84)90095-2.
6
7
8
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.一种新型单克隆抗体（DF3）对人类恶性与良性乳腺肿瘤的不同反应性。
Hybridoma. 1984 Fall;3(3):223-32. doi: 10.1089/hyb.1984.3.223.
9
Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study.一项针对400例患者的癌胚抗原二次观察结直肠癌研究的结果。
Cancer. 1985 Mar 15;55(6):1284-90. doi: 10.1002/1097-0142(19850315)55:6<1284::aid-cncr2820550622>3.0.co;2-b.
10
MAM-6 antigen, a new serum marker for breast cancer monitoring.
Cancer Res. 1986 May;46(5):2582-7.
Zotero 插件